

Werner B F Brouwer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2622704/publications.pdf>

Version: 2024-02-01

182
papers

7,851
citations

50276

46
h-index

64796

79
g-index

186
all docs

186
docs citations

186
times ranked

7980
citing authors

#	ARTICLE	IF	CITATIONS
1	Psychometric evaluation of the Health-Risk Attitude Scale (HRAS-13): assessing the reliability, dimensionality and validity in the general population and a patient population. <i>Psychology and Health</i> , 2022, 37, 34-50.	2.2	5
2	Did the COVID-19 pandemic change the willingness to pay for an early warning system for infectious diseases in Europe?. <i>European Journal of Health Economics</i> , 2022, 23, 81-94.	2.8	4
3	The Mental Health Quality of Life Questionnaire (MHQoL): development and first psychometric evaluation of a new measure to assess quality of life in people with mental health problems. <i>Quality of Life Research</i> , 2022, 31, 633-643.	3.1	22
4	Do Profit Margins of Pharmaceuticals Influence Reimbursement Decisions? A Discrete Choice Experiment Among Dutch Healthcare Decision Makers. <i>Value in Health</i> , 2022, 25, 222-229.	0.3	3
5	Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic. <i>Pharmacoeconomics</i> , 2022, 40, 77-90.	3.3	13
6	Caring for Children with an Autism Spectrum Disorder: Factors Associating with Health- and Care-Related Quality of Life of the Caregivers. <i>Journal of Autism and Developmental Disorders</i> , 2022, 52, 4665-4678.	2.7	5
7	The relative value of carer and patient quality of life: A person trade-off (PTO) study. <i>Social Science and Medicine</i> , 2022, 292, 114556.	3.8	10
8	Coverage with evidence development for medical devices in Europe: Can practice meet theory?. <i>Health Economics (United Kingdom)</i> , 2022, 31, 179-194.	1.7	6
9	Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries. <i>Health Economics (United Kingdom)</i> , 2022, , .	1.7	5
10	Estimating an anchored utility tariff for the well-being of older people measure (WOOP) for the Netherlands. <i>Social Science and Medicine</i> , 2022, 301, 114901.	3.8	7
11	In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era. <i>Pharmacoeconomics</i> , 2022, 40, 7-11.	3.3	6
12	Broadening the application of health technology assessment in the Netherlands: a worthwhile destination but not an easy ride?. <i>Health Economics, Policy and Law</i> , 2021, 16, 440-456.	1.8	10
13	Validation of the Hungarian version of the CarerQoL instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary. <i>Quality of Life Research</i> , 2021, 30, 629-641.	3.1	6
14	A validation study of the CarerQoL instrument in informal caregivers of people with dementia from eight European countries. <i>Quality of Life Research</i> , 2021, 30, 577-588.	3.1	11
15	What works better for preference elicitation among older people? Cognitive burden of discrete choice experiment and case 2 best-worst scaling in an online setting. <i>Journal of Choice Modelling</i> , 2021, 38, 100265.	2.3	11
16	Performance-based risk-sharing agreements in renal care: current experience and future prospects. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 197-210.	1.4	2
17	Trust me; I know what I am doing investigating the effect of choice list elicitation and domain-relevant training on preference reversals in decision making for others. <i>European Journal of Health Economics</i> , 2021, 22, 679-697.	2.8	2
18	Risk communication during COVID-19: A descriptive study on familiarity with, adherence to and trust in the WHO preventive measures. <i>PLoS ONE</i> , 2021, 16, e0250872.	2.5	41

#	ARTICLE	IF	CITATIONS
19	Blood donation in times of crisis: Early insight into the impact of COVID-19 on blood donors and their motivation to donate across European countries. <i>Vox Sanguinis</i> , 2021, 116, 1031-1041.	1.5	30
20	The value of health—Empirical issues when estimating the monetary value of a quality-adjusted life year based on well-being data. <i>Health Economics (United Kingdom)</i> , 2021, 30, 1849-1870.	1.7	2
21	Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges. <i>European Journal of Health Economics</i> , 2021, 22, 1253-1273.	2.8	13
22	Don't forget about the future: The impact of including future costs on the cost-effectiveness of adult pneumococcal conjugate vaccination with PCV13 in the Netherlands. <i>Vaccine</i> , 2021, 39, 3834-3843.	3.8	4
23	Willingness to pay for quality and length of life gains in end of life patients of different ages. <i>Social Science and Medicine</i> , 2021, 279, 113987.	3.8	5
24	Distributional consequences of including survivor costs in economic evaluations. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2606-2613.	1.7	3
25	Content validation of the Well-being of Older People measure (WOOP). <i>Health and Quality of Life Outcomes</i> , 2021, 19, 200.	2.4	11
26	Estimating an exchange rate between care-related and health-related quality of life outcomes for economic evaluation: An application of the wellbeing valuation method. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2847-2857.	1.7	5
27	Life satisfaction: The role of domain-specific reference points. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2766-2779.	1.7	5
28	Development and psychometric evaluation of the Decision Tool Anxiety Disorders, OCD and PTSD (DTAOP): Facilitating the early detection of patients in need of highly specialized care. <i>PLoS ONE</i> , 2021, 16, e0256384.	2.5	0
29	Willingness to Pay for Health-Related Quality of Life Gains in Relation to Disease Severity and the Age of Patients. <i>Value in Health</i> , 2021, 24, 1182-1192.	0.3	18
30	Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective. <i>Value in Health</i> , 2021, 24, 1686-1699.	0.3	21
31	Good Days and Bad Days: Measuring Health-Related Quality of Life in People With Epilepsy. <i>Value in Health</i> , 2021, 24, 1470-1475.	0.3	3
32	Estimating the costs of non-medical consumption in life-years gained for economic evaluations. <i>Social Science and Medicine</i> , 2021, 289, 114414.	3.8	3
33	Mixed evidence for the compression of morbidity hypothesis for smoking elimination—a systematic literature review. <i>European Journal of Public Health</i> , 2021, 31, 409-417.	0.3	3
34	Instruments to assess quality of life in people with mental health problems: a systematic review and dimension analysis of generic, domain- and disease-specific instruments. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 249.	2.4	11
35	Children with an Autism Spectrum Disorder and Their Caregivers: Capturing Health-Related and Care-Related Quality of Life. <i>Journal of Autism and Developmental Disorders</i> , 2020, 50, 263-277.	2.7	40
36	A validation study of the ICECAP-O in informal carers of people with dementia from eight European Countries. <i>Quality of Life Research</i> , 2020, 29, 237-251.	3.1	8

#	ARTICLE	IF	CITATIONS
37	How does participating in a deliberative citizens panel on healthcare priority setting influence the views of participants?. <i>Health Policy</i> , 2020, 124, 143-151.	3.0	11
38	Lifecycle evidence requirements for high-risk implantable medical devices: a European perspective. <i>Expert Review of Medical Devices</i> , 2020, 17, 993-1006.	2.8	15
39	Estimating the monetary value of health and capability well-being applying the well-being valuation approach. <i>European Journal of Health Economics</i> , 2020, 21, 1235-1244.	2.8	10
40	Acceptable health and ageing: results of a cross-sectional study from Hungary. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 346.	2.4	3
41	The Healthy Aging Index analyzed over 15 years in the general population: The Doetinchem Cohort Study. <i>Preventive Medicine</i> , 2020, 139, 106193.	3.4	13
42	Development and psychometric evaluation of the Transdiagnostic Decision Tool: matched care for patients with a mental disorder in need of highly specialised care. <i>BJPsych Open</i> , 2020, 6, .	0.7	0
43	What is it going to be, TTO or SG? A direct test of the validity of health state valuation. <i>Health Economics (United Kingdom)</i> , 2020, 29, 1475-1481.	1.7	13
44	Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature. <i>European Journal of Health Economics</i> , 2020, 21, 1329-1350.	2.8	3
45	Living up to expectations: Experimental tests of subjective life expectancy as reference point in time trade-off and standard gamble. <i>Journal of Health Economics</i> , 2020, 71, 102318.	2.7	12
46	Happy with Your Capabilities? Valuing ICECAP-O and ICECAP-A States Based on Experienced Utility Using Subjective Well-Being Data. <i>Medical Decision Making</i> , 2020, 40, 498-510.	2.4	5
47	Willingness to pay for an early warning system for infectious diseases. <i>European Journal of Health Economics</i> , 2020, 21, 763-773.	2.8	20
48	Costs and benefits of early response in the Ebola virus disease outbreak in Sierra Leone. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 13.	1.5	11
49	Development of Population Tariffs for the CarerQoL Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving. <i>Pharmacoeconomics</i> , 2020, 38, 633-643.	3.3	6
50	Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. <i>European Journal of Health Economics</i> , 2020, 21, 977-982.	2.8	760
51	United but divided: Policy responses and people's perceptions in the EU during the COVID-19 outbreak. <i>Health Policy</i> , 2020, 124, 909-918.	3.0	147
52	Well-being of Older People (WOOP): Quantitative validation of a new outcome measure for use in economic evaluations. <i>Social Science and Medicine</i> , 2020, 259, 113109.	3.8	14
53	Challenges with coverage with evidence development schemes for medical devices: A systematic review. <i>Health Policy and Technology</i> , 2020, 9, 146-156.	2.5	15
54	How do combinations of unhealthy behaviors relate to attitudinal factors and subjective health among the adult population in the Netherlands?. <i>BMC Public Health</i> , 2020, 20, 441.	2.9	22

#	ARTICLE	IF	CITATIONS
55	Challenges in economic evaluations in obstetric care: a scoping review and expert opinion. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 1399-1407.	2.3	4
56	Title is missing!. , 2020, 15, e0238858.		0
57	Title is missing!. , 2020, 15, e0238858.		0
58	Title is missing!. , 2020, 15, e0238858.		0
59	Title is missing!. , 2020, 15, e0238858.		0
60	QALYs without bias? Nonparametric correction of time trade-off and standard gamble weights based on prospect theory. Health Economics (United Kingdom), 2019, 28, 843-854.	1.7	24
61	The Corrective Approach: Policy Implications of Recent Developments in QALY Measurement Based on Prospect Theory. Value in Health, 2019, 22, 816-821.	0.3	12
62	Equity Weights for Priority Setting in Healthcare: Severity, Age, or Both?. Value in Health, 2019, 22, 1441-1449.	0.3	28
63	Views of older people in the Netherlands on wellbeing: A Q-methodology study. Social Science and Medicine, 2019, 240, 112535.	3.8	19
64	How to value safety in economic evaluations in health care? A review of applications in different sectors. European Journal of Health Economics, 2019, 20, 1041-1061.	2.8	11
65	Severity-Adjusted Probability of Being Cost Effective. Pharmacoeconomics, 2019, 37, 1155-1163.	3.3	50
66	The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys. European Journal of Health Economics, 2019, 20, 5-16.	2.8	22
67	The decision tool unipolar depression (DTUD): a new measure to facilitate the early identification of patients with major depressive disorder in need of highly specialized care. BMC Psychiatry, 2019, 19, 179.	2.6	4
68	Measuring Health Spillover Effects in Caregivers of Children with Autism Spectrum Disorder: A Comparison of the EQ-5D-3L and SF-6D. Pharmacoeconomics, 2019, 37, 609-620.	3.3	22
69	How to govern the digital transformation of health services. European Journal of Public Health, 2019, 29, 7-12.	0.3	98
70	When is it too expensive? Cost-effectiveness thresholds and health care decision-making. European Journal of Health Economics, 2019, 20, 175-180.	2.8	73
71	Future Costs in Cost-Effectiveness Analyses: Past, Present, Future. Pharmacoeconomics, 2019, 37, 119-130.	3.3	33
72	Does the ICECAP-O cover the physical, mental and social functioning of older people in the UK?. Quality of Life Research, 2019, 28, 761-770.	3.1	14

#	ARTICLE	IF	CITATIONS
73	The Monetary Value of Informal Care: Obtaining Pure Time Valuations Using a Discrete Choice Experiment. <i>Pharmacoeconomics</i> , 2019, 37, 531-540.	3.3	20
74	The Inclusion of Spillover Effects in Economic Evaluations: Not an Optional Extra. <i>Pharmacoeconomics</i> , 2019, 37, 451-456.	3.3	48
75	A QALY loss is a QALY loss is a QALY loss: a note on independence of loss aversion from health states. <i>European Journal of Health Economics</i> , 2019, 20, 419-426.	2.8	10
76	Integrating clinical and economic evidence in clinical guidelines: More needed than ever!. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 561-564.	1.8	6
77	A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. <i>Health Economics (United Kingdom)</i> , 2019, 28, 87-100.	1.7	39
78	Future unrelated medical costs need to be considered in cost effectiveness analysis. <i>European Journal of Health Economics</i> , 2019, 20, 1-5.	2.8	25
79	Indicators to facilitate the early identification of patients with major depressive disorder in need of highly specialized care: A concept mapping study. <i>Depression and Anxiety</i> , 2018, 35, 346-352.	4.1	6
80	Are people living with HIV less productive at work?. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1265-1272.	1.2	8
81	Looking back and moving forward: On the application of proportional shortfall in healthcare priority setting in the Netherlands. <i>Health Policy</i> , 2018, 122, 621-629.	3.0	55
82	What should we know about the person behind a TTO?. <i>European Journal of Health Economics</i> , 2018, 19, 1207-1211.	2.8	12
83	New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year. <i>European Journal of Health Economics</i> , 2018, 19, 277-291.	2.8	9
84	Peer effects in health valuation: the relation between rating of contemporaries' health and own health. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 148.	2.4	2
85	Discounting in Economic Evaluations. <i>Pharmacoeconomics</i> , 2018, 36, 745-758.	3.3	210
86	Who should receive treatment? An empirical enquiry into the relationship between societal views and preferences concerning healthcare priority setting. <i>PLoS ONE</i> , 2018, 13, e0198761.	2.5	14
87	Time Is Money: Investigating the Value of Leisure Time and Unpaid Work. <i>Value in Health</i> , 2018, 21, 1428-1436.	0.3	38
88	A short note on measuring subjective life expectancy: survival probabilities versus point estimates. <i>European Journal of Health Economics</i> , 2017, 18, 7-12.	2.8	6
89	Priority to End of Life Treatments? Views of the Public in the Netherlands. <i>Value in Health</i> , 2017, 20, 107-117.	0.3	22
90	Acceptable health and priority weighting: Discussing a reference-level approach using sufficientarian reasoning. <i>Social Science and Medicine</i> , 2017, 181, 158-167.	3.8	9

#	ARTICLE	IF	CITATIONS
91	Valid Outcome Measures in Care for Older People: Comparing the ASCOT and the ICECAP-O. <i>Value in Health</i> , 2017, 20, 936-944.	0.3	22
92	Measuring Care-Related Quality of Life of Caregivers for Use in Economic Evaluations: CarerQol Tariffs for Australia, Germany, Sweden, UK, and US. <i>Pharmacoeconomics</i> , 2017, 35, 469-478.	3.3	46
93	The Challenge of Conditional Reimbursement: Stopping Reimbursement Can Be More Difficult Than Not Starting in the First Place!. <i>Value in Health</i> , 2017, 20, 118-125.	0.3	31
94	Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness Analysis. <i>Health Economics (United Kingdom)</i> , 2016, 25, 237-248.	1.7	41
95	The Impact of Hospital Payment Schemes on Healthcare and Mortality: Evidence from Hospital Payment Reforms in OECD Countries. <i>Health Economics (United Kingdom)</i> , 2016, 25, 1005-1019.	1.7	12
96	From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare. <i>Pharmacoeconomics</i> , 2016, 34, 1071-1074.	3.3	74
97	Altruistic Preferences in Time Tradeoff. <i>Medical Decision Making</i> , 2016, 36, 187-198.	2.4	11
98	Patient and general public preferences for health states: A call to reconsider current guidelines. <i>Social Science and Medicine</i> , 2016, 165, 66-74.	3.8	110
99	Measuring Health Spillovers for Economic Evaluation: A Case Study in Meningitis. <i>Health Economics (United Kingdom)</i> , 2016, 25, 1529-1544.	1.7	68
100	From representing views to representativeness of views: Illustrating a new (Q2S) approach in the context of health care priority setting in nine European countries. <i>Social Science and Medicine</i> , 2016, 166, 205-213.	3.8	19
101	Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. <i>Health Economics (United Kingdom)</i> , 2016, 25, 933-938.	1.7	23
102	“Back to the future”: Influence of beliefs regarding the future on TTO answers. <i>Health and Quality of Life Outcomes</i> , 2016, 14, 4.	2.4	9
103	Are some QALYs more equal than others?. <i>European Journal of Health Economics</i> , 2016, 17, 117-127.	2.8	24
104	A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs. <i>European Journal of Health Economics</i> , 2016, 17, 391-402.	2.8	39
105	Exploring a new method for deriving the monetary value of a QALY. <i>European Journal of Health Economics</i> , 2016, 17, 801-809.	2.8	12
106	A long life in good health: subjective expectations regarding length and future health-related quality of life. <i>European Journal of Health Economics</i> , 2016, 17, 577-589.	2.8	30
107	A Framework for Including Family Health Spillovers in Economic Evaluation. <i>Medical Decision Making</i> , 2016, 36, 176-186.	2.4	82
108	Rational expectations? An explorative study of subjective survival probabilities and lifestyle across Europe. <i>Health Expectations</i> , 2016, 19, 121-137.	2.6	21

#	ARTICLE	IF	CITATIONS
109	The perseverance time of informal carers for people with dementia: results of a two-year longitudinal follow-up study. <i>BMC Nursing</i> , 2015, 14, 56.	2.5	12
110	Does living longer in good health facilitate longer working lives? The relationship between disability and working lives. <i>European Journal of Public Health</i> , 2015, 25, 791-795.	0.3	14
111	Public views on principles for health care priority setting: Findings of a European cross-country study using Q methodology. <i>Social Science and Medicine</i> , 2015, 126, 128-137.	3.8	108
112	Did the health of the Dutch population improve between 2001 and 2008? Investigating age- and gender-specific trends in quality of life. <i>European Journal of Health Economics</i> , 2015, 16, 801-811.	2.8	7
113	Treatment for Sleep Problems in Children with Autism and Caregiver Spillover Effects. <i>Journal of Autism and Developmental Disorders</i> , 2015, 45, 3613-3623.	2.7	56
114	Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment. <i>Pharmacoeconomics</i> , 2015, 33, 1289-1300.	3.3	31
115	“Married with children” the influence of significant others in TTO exercises. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 94.	2.4	18
116	Are all health gains equally important? An exploration of acceptable health as a reference point in health care priority setting. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 79.	2.4	21
117	The iMTA Productivity Cost Questionnaire. <i>Value in Health</i> , 2015, 18, 753-758.	0.3	298
118	Primary care in cancer control: towards mature cancer care. <i>Lancet Oncology</i> , The, 2015, 16, 1226-1227.	10.7	3
119	Unpaid work in health economic evaluations. <i>Social Science and Medicine</i> , 2015, 144, 127-137.	3.8	42
120	The Perseverance Time of Informal Carers of Dementia Patients: Validation of a New Measure to Initiate Transition of Care at Home to Nursing Home Care. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 631-642.	2.6	30
121	A Discrete Choice Experiment to Obtain a Tariff for Valuing Informal Care Situations Measured with the CarerQol Instrument. <i>Medical Decision Making</i> , 2014, 34, 84-96.	2.4	63
122	Subjective expectations regarding length and health-related quality of life in Hungary: results from an empirical investigation. <i>Health Expectations</i> , 2014, 17, 696-709.	2.6	24
123	Quality of life instruments for economic evaluations in health and social care for older people: A systematic review. <i>Social Science and Medicine</i> , 2014, 102, 83-93.	3.8	146
124	Predicting productivity based on EQ-5D: an explorative study. <i>European Journal of Health Economics</i> , 2014, 15, 465-475.	2.8	19
125	The Value of a QALY: Individual Willingness to Pay for Health Gains Under Risk. <i>Pharmacoeconomics</i> , 2014, 32, 75-86.	3.3	50
126	How to Estimate Productivity Costs in Economic Evaluations. <i>Pharmacoeconomics</i> , 2014, 32, 335-344.	3.3	144

#	ARTICLE	IF	CITATIONS
127	Quality of Life of Nursing Home Residents with Dementia: Validation of the German Version of the ICECAP-O. PLoS ONE, 2014, 9, e92016.	2.5	41
128	Measuring the impact of caregiving on informal carers: a construct validation study of the CarerQol instrument. Health and Quality of Life Outcomes, 2013, 11, 173.	2.4	74
129	How to Include Informal Care in Economic Evaluations. Pharmacoeconomics, 2013, 31, 1105-1119.	3.3	115
130	Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.. Pharmacoeconomics, 2013, 31, 369-373.	3.3	12
131	Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall. European Journal of Health Economics, 2013, 14, 107-115.	2.8	80
132	The impact of informal care for patients with Pompe disease: An application of the CarerQol instrument. Molecular Genetics and Metabolism, 2013, 110, 281-286.	1.1	18
133	VALUING QALY GAINS BY APPLYING A SOCIETAL PERSPECTIVE. Health Economics (United Kingdom), 2013, 22, 1272-1281.	1.7	49
134	The evaluation of lifestyle interventions in the Netherlands. Health Economics, Policy and Law, 2012, 7, 243-261.	1.8	2
135	Inquiry into the Relationship between Equity Weights and the Value of the QALY. Value in Health, 2012, 15, 1119-1126.	0.3	43
136	Subjective caregiver burden of parents of adults with Duchenne muscular dystrophy. Disability and Rehabilitation, 2012, 34, 988-996.	1.8	85
137	GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation. Journal of Health Economics, 2012, 31, 158-168.	2.7	45
138	Does the EQ-5D Reflect Lost Earnings?. Pharmacoeconomics, 2012, 30, 47-61.	3.3	25
139	Capabilities and quality of life in Dutch psycho-geriatric nursing homes: an exploratory study using a proxy version of the ICECAP-O. Quality of Life Research, 2012, 21, 801-812.	3.1	59
140	Do Productivity Costs Matter?. Pharmacoeconomics, 2011, 29, 601-619.	3.3	102
141	A new test of the construct validity of the CarerQol instrument: measuring the impact of informal care giving. Quality of Life Research, 2011, 20, 875-887.	3.1	75
142	Discounting and decision making in the economic evaluation of health-care technologies. Health Economics (United Kingdom), 2011, 20, 2-15.	1.7	156
143	Health Effects in Significant Others. Medical Decision Making, 2011, 31, 292-298.	2.4	77
144	Sustained informal care: The feasibility, construct validity and test-retest reliability of the CarerQol-instrument to measure the impact of informal care in long-term care. Aging and Mental Health, 2011, 15, 1018-1027.	2.8	54

#	ARTICLE	IF	CITATIONS
145	The efficiency frontier approach to economic evaluation: will it help German policy making?. Health Economics (United Kingdom), 2010, 19, 1128-1131.	1.7	16
146	The Value of Correcting Values: Influence and Importance of Correcting TTO Scores for Time Preference. Value in Health, 2010, 13, 879-884.	0.3	23
147	Willingness to Pay for a Quality-Adjusted Life-Year: The Individual Perspective. Value in Health, 2010, 13, 1046-1055.	0.3	88
148	Lifestyle intervention: from cost savings to value for money. Journal of Public Health, 2010, 32, 440-447.	1.8	28
149	Caring for and caring about: Disentangling the caregiver effect and the family effect. Journal of Health Economics, 2010, 29, 549-556.	2.7	153
150	Some pain, no gain: experiences with the no-claim rebate in the Dutch health care system. Health Economics, Policy and Law, 2009, 4, 405-424.	1.8	8
151	The Incorporation of Income and Leisure in Health State Valuations When the Measure Is Silent: An Empirical Inquiry into the Sound of Silence. Medical Decision Making, 2009, 29, 503-512.	2.4	12
152	The influence of subjective life expectancy on health state valuations using a 10 year TTO. Health Economics (United Kingdom), 2009, 18, 549-558.	1.7	51
153	Breaking the Silence: Exploring the Potential Effects of Explicit Instructions on Incorporating Income and Leisure in TTO Exercises. Value in Health, 2009, 12, 172-180.	0.3	14
154	I costi sanitari indiretti (non correlati) durante gli anni di vita guadagnati. Pharmacoeconomics Italian Research Articles, 2009, 11, 55-70.	0.2	1
155	Can we fix it? Yes we can! But what? A new test of procedural invariance in TTO measurement. Health Economics (United Kingdom), 2008, 17, 877-885.	1.7	18
156	Welfarism vs. extra-welfarism. Journal of Health Economics, 2008, 27, 325-338.	2.7	260
157	Give me a break!. Health Policy, 2008, 88, 73-87.	3.0	71
158	The New Myth. Pharmacoeconomics, 2008, 26, 1-4.	3.3	34
159	Unrelated Medical Costs in Life-Years Gained. Pharmacoeconomics, 2008, 26, 815-830.	3.3	68
160	Una panoramica delle metodologie per la valutazione delle cure informali negli studi di economia sanitaria. Pharmacoeconomics Italian Research Articles, 2008, 10, 99-111.	0.2	0
161	The invisible hands made visible: recognizing the value of informal care in healthcare decision-making. Expert Review of Pharmacoeconomics and Outcomes Research, 2008, 8, 557-561.	1.4	37
162	Economics and public health: engaged to be happily married!. European Journal of Public Health, 2007, 17, 122-123.	0.3	15

#	ARTICLE	IF	CITATIONS
163	Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Economics (United Kingdom), 2007, 16, 307-317.	1.7	103
164	Too Important to Ignore. Pharmacoeconomics, 2006, 24, 39-41.	3.3	50
165	A Dollar Is a Dollar Is a Dollarâ€™or Is It?. Value in Health, 2006, 9, 341-347.	0.3	63
166	The CarerQol instrument: A new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations. Quality of Life Research, 2006, 15, 1005-1021.	3.1	298
167	Acceptability of less than perfect health states. Social Science and Medicine, 2005, 60, 237-246.	3.8	56
168	Expectations regarding length and health related quality of life: Some empirical findings. Social Science and Medicine, 2005, 61, 1083-1094.	3.8	50
169	The Relationship between Productivity and Health-Related QOL. Pharmacoeconomics, 2005, 23, 209-218.	3.3	54
170	Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ: British Medical Journal, 2005, 331, 446-448.	2.3	171
171	Process utility from providing informal care: the benefit of caring. Health Policy, 2005, 74, 85-99.	3.0	158
172	The influence of subjective expectations about length and quality of life on time trade-off answers. Health Economics (United Kingdom), 2004, 13, 819-823.	1.7	36
173	Reconciliation of Economic Concerns and Health Policy. Pharmacoeconomics, 2004, 22, 1097-1107.	3.3	95
174	Discounting in decision making: the consistency argument revisited empirically. Health Policy, 2004, 67, 187-194.	3.0	16
175	The missing link: on the line between C and E. Health Economics (United Kingdom), 2003, 12, 629-636.	1.7	26
176	Should I stay or should I go? Waiting lists and cross-border care in the Netherlands. Health Policy, 2003, 63, 289-298.	3.0	50
177	Productivity costs before and after absence from work: as important as common?. Health Policy, 2002, 61, 173-187.	3.0	73
178	Priority care for employees: A blessing in disguise?. , 1999, 8, 65-73.		22
179	Productivity losses without absence: measurement validation and empirical evidence. Health Policy, 1999, 48, 13-27.	3.0	199
180	How to Calculate Indirect Costs in Economic Evaluations. Pharmacoeconomics, 1998, 13, 563-569.	3.3	30

#	ARTICLE	IF	CITATIONS
181	Productivity Costs Measurement Through Quality of Life? A Response to the Recommendation of the Washington Panel. , 1997, 6, 253-259.		136
182	Productivity Costs Measurement Through Quality of Life? A Response to the Recommendation of the Washington Panel. Health Economics (United Kingdom), 1997, 6, 253-259.	1.7	4